Chronotropic Incompetence During Exercise Testing in Obese Adolescents

Sponsor
Hasselt University (Other)
Overall Status
Unknown status
CT.gov ID
NCT04185753
Collaborator
(none)
60
1
2
29.5

Study Details

Study Description

Brief Summary

In adolescents with obesity cardiopulmonary exercise testing (CPET) has become an important clinical examination providing valuable information with regard to the integrative exercise responses, including the pulmonary, cardiovascular and muscular systems.

During CPET, mechanical constraints in ventilation, an elevated risk for hypoxia and chronotropic incompetence (CI) (defined as the inability of the heart to increase its rate with increased activity), or compromised cardiac function (e.g. lowered heart rate (HR) recovery, chronotropic index and stroke volume) are often observed in obese adults. Moreover, several studies regarding exercise capacity and cardiopulmonary responses to maximal endurance exercise testing have been performed in obese adolescents. Despite these previous investigations in obese adolescents it remains controversial whether cardiopulmonary disturbances can be observed consistently during CPET. However, a number of studies have reported a suboptimal response to exercise, in particular a reduced peak heart rate (HRpeak) and peak cycling power output (Wpeak). Adult obesity modifies cardiac behavior, including resting HR and CI, which has a marked effect on exercise capacity. Therefore, chronotropic variables are the most important factors that affect exercise performance. It has been shown that both peak and resting HR account for over forty percent of variability of exercise capacity. Interestingly, resting HR and HR response to exercise, including a blunted HR increase, low chronotropic index and HR recovery, are important predictors of all-cause mortality and cardiovascular death, at least in adults. These changes in HR during and recovery from CPET are mediated by the balance between sympathetic and vagal activity of the autonomic nervous system. Adverse cardiovascular outcomes associated with the metabolic syndrome may be mediated by autonomic dysfunction, whereby obesity is characterized by sympathetic predominance and a decrease in vagal activity in the basal state, where reduced sympathetic responsiveness has been observed during exercise. Therefore, these multiple exercise risk markers could provide valuable clinical information regarding cardiometabolic health. Nonetheless HR behavior during CPET has not been described in obese adolescents. The goal of this study is to examine the HR behavior of obese adolescents during CPET to clarify whether this population suffer from CI.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: The prevalence of chronotropic incompetence during maximal cardiopulmonary exercise testing

Study Design

Study Type:
Observational
Anticipated Enrollment :
60 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
Chronotropic Incompetence During Cardiopulmonary Exercise Testing in Obese Adolescents: Associations With Caridometabolic Health
Anticipated Study Start Date :
Nov 29, 2019
Anticipated Primary Completion Date :
Jan 15, 2020
Anticipated Study Completion Date :
Jan 30, 2020

Arms and Interventions

Arm Intervention/Treatment
Obese adolescents with CI

Obese adolescents with chronotropic incompetence

Diagnostic Test: The prevalence of chronotropic incompetence during maximal cardiopulmonary exercise testing
The prevalence of chronotropic incompetence during maximal cardiopulmonary exercise testing

Control group

Obese adolescents without chronotropic incompetence

Diagnostic Test: The prevalence of chronotropic incompetence during maximal cardiopulmonary exercise testing
The prevalence of chronotropic incompetence during maximal cardiopulmonary exercise testing

Outcome Measures

Primary Outcome Measures

  1. Heart rate (HR) during exercise testing [day 1]

    Assessed using a 12-lead ECG device

  2. Peak oxygen uptake (VO2) during exercise testing [day 1]

    Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed. With the aid of continuous pulmonary gas exchange analysis VO2 is collected breath-by-breath and averaged every ten seconds.

  3. Peak workload during exercise testing [day 1]

    Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed and the incremental workload is measured

Secondary Outcome Measures

  1. Body height [day 1]

    Body height is measured to the nearest 0.1cm using a wall-mounted Harpenden stadiometer, with participants barefoot

  2. Body weight [day 1]

    Body weight (in underwear) is determined using a digital-balanced weighting scale to the nearest 0.1kg

  3. Waist circumference [day 1]

    Waist circumference will be measured to the nearest 0.1cm using a flexible metric measuring tape with participants barefoot (in underwear) in standing position. Waist circumference is measured at the midpoint between the lower rib margin and the top of the iliac crest.

  4. Hip circumference [day1]

    Hip circumference will be measured to the nearest 0.1cm using a flexible metric measuring tape with participants barefoot (in underwear) in standing position. Hip circumference is measured at the widest circumference of the hip at the level of the greater trochanter.

  5. Physical activity questionnaire for adolescents (PAQ-A) [day 1]

    physical activity determined using the validated Dutch physical activity questionnaire for adolescents

  6. Tanner stage [day 1]

    Puberty stage (ranging from 1 to 5) will be assessed in all participants by the pediatric endocrinologist using Tanner staging criteria.

  7. Plasma glucose [day 1]

    Blood analyses

  8. Total cholesterol [day 1]

    Blood analyses

  9. High-density lipoprotein cholesterol [day 1]

    Blood analyses

  10. Low-density lipoprotein cholesterol [day 1]

    Blood analyses

  11. Triglyceride concentration [day 1]

    Blood analyses

  12. C-reactive protein [day 1]

    Blood analyses

  13. Serum leptin concentration [day 1]

    Blood analyses

  14. Insulin [day 1]

    Blood analyses

  15. Homeostatic model assessment for insulin resistance (HOMA-IR) [day 1]

    Homeostatic model assessment for insulin resistance calculated from insulin and glucose concentration

  16. Carbon dioxide output (VCO2) during exercise testing [day 1]

    Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed. With the aid of continuous pulmonary gas exchange analysis VCO2 is collected breath-by-breath and averaged every ten seconds.

  17. Minute ventilation(VE) during exercise testing [day 1]

    Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed. With the aid of continuous pulmonary gas exchange analysis VE is collected breath-by-breath and averaged every ten seconds.

  18. Tidal volume (Vt) during exercise testing [day 1]

    Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed. With the aid of continuous pulmonary gas exchange analysis Vt is collected breath-by-breath and averaged every ten seconds.

  19. Breathing frequency (BF) during exercise testing [day 1]

    Cardiopulmonary exercise test on an electronically braked cycle ergometer is performed. With the aid of continuous pulmonary gas exchange analysis BF is collected breath-by-breath and averaged every ten seconds.

Eligibility Criteria

Criteria

Ages Eligible for Study:
11 Years to 17 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  • obese or lean (based on extended international (IOTF) body mass index cut-offs for thinness, overweight and obesity)

  • Parental permission

Exclusion Criteria:
  • Chronic cardiovascular, renal, pulmonary or orthopaedic disease

  • Medication use that could possibly influence the heart rate

Contacts and Locations

Locations

Site City State Country Postal Code
1 Virga Jesse hospital - Heart centre Hasselt Hasselt Limburg Belgium 3500

Sponsors and Collaborators

  • Hasselt University

Investigators

  • Principal Investigator: Dominique Hansen, PhD, Hasselt University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Dominique Hansen, Principal Investigator, Hasselt University
ClinicalTrials.gov Identifier:
NCT04185753
Other Study ID Numbers:
  • CIDCET study
First Posted:
Dec 4, 2019
Last Update Posted:
Dec 4, 2019
Last Verified:
Dec 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 4, 2019